Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax and BioNTech Stocks Are Jumping Today

By Keith Speights - Updated Apr 13, 2021 at 11:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news for J&J could be good news for these biotechs.

What happened

Shares of Novavax (NVAX -1.17%) were jumping 10.9% as of 10:51 a.m. EDT on Tuesday, while BioNTech (BNTX -0.52%) was up nearly 5%. The gains for both stocks came after the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) jointly recommended pausing the use of Johnson & Johnson's (JNJ 0.09%) COVID-19 vaccine after a few cases of blood clots were reported in individuals who received the vaccine.

So what

It's par for the course for biotech stocks to benefit from bad news for a rival. There's a possibility that both Novavax and BioNTech could sell more of their respective COVID-19 vaccines due to J&J's issues.

COVID-19 vaccine vial and syringe on top of a stock chart

Image source: Getty Images.

BioNTech and its partner Pfizer already have a supply deal with the U.S. government for 300 million doses of their BNT162b2 vaccine. Should the pause in the use of J&J's vaccine become a longer-term suspension, it wouldn't be surprising for the U.S. to raise its order for doses of BNT162b2.

Novavax hasn't yet won Emergency Use Authorization for its COVID-19 vaccine. But the biotech appears to be on track to potentially win authorization within the next few months. It is currently obligated to supply 100 million doses to the U.S. The company could also see that number rise if J&J's problems persist.

All of this speculation is very premature, though. So far, there have been only six cases of a rare type of blood clot reported with more than 6.8 million doses of J&J's vaccine administered. Any pause in the use of the vaccine could be only temporary.

Now what

Investors should wait and see what the CDC and FDA determine. Regardless of what happens with J&J's vaccine, though, the prospects for BioNTech and Novavax should still be quite good.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$63.54 (-1.17%) $0.75
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.30 (0.09%) $0.16
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.75 (2.15%) $1.11
BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.20 (-0.52%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.